Data on Vitrakvi (larotrectinib) in adult and pediatric patients with TRK fusion cancer shows the need to identify suitable patients through genomic testing, says German pharma major Bayer (BAYN: DE).
The largest dataset to date on patients with TRK fusion cancer has been published in The Lancet Oncology, showing an overall response rate (ORR) of 79%, with 16% complete responses and 63% partial responses in 153 evaluable patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze